Nyxoah SA (NASDAQ:NYXH) Short Interest Update

Nyxoah SA (NASDAQ:NYXH) was the target of a large increase in short interest in June. As of June 15th, there was short interest totaling 826,117 shares, an increase of 185.5% from the May 31st total of 289,376 shares. Based on an average daily trading volume, of 965,701 shares, the short-interest ratio is presently 0.9 days. Approximately 2.6% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

NYXH has been the subject of several research reports. Weiss Ratings lowered shares of Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. Piper Sandler reiterated an “overweight” rating and set a $7.00 price objective (down from $9.00) on shares of Nyxoah in a research report on Wednesday, May 13th. Stifel Nicolaus decreased their price objective on Nyxoah from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Wednesday, June 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 price target on shares of Nyxoah in a research report on Monday, March 23rd. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Nyxoah presently has an average rating of “Hold” and an average target price of $7.00.

Institutional Trading of Nyxoah

Large investors have recently added to or reduced their stakes in the stock. Heights Capital Management Inc. purchased a new position in shares of Nyxoah during the fourth quarter valued at about $3,575,000. Deutsche Bank AG boosted its position in shares of Nyxoah by 40.0% during the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after purchasing an additional 10,000 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Nyxoah in the third quarter worth $98,000. Bank of America Corp DE raised its holdings in Nyxoah by 152.7% in the third quarter. Bank of America Corp DE now owns 19,878 shares of the company’s stock worth $91,000 after purchasing an additional 12,012 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its position in Nyxoah by 35.6% during the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock valued at $59,000 after buying an additional 3,353 shares during the period.

Nyxoah Trading Down 1.2%

Nyxoah stock traded down $0.02 during trading hours on Monday, reaching $1.65. The company had a trading volume of 102,228 shares, compared to its average volume of 710,527. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.99 and a quick ratio of 0.88. Nyxoah has a 12-month low of $1.26 and a 12-month high of $8.59. The company has a 50-day moving average price of $2.50 and a 200 day moving average price of $3.60. The firm has a market cap of $63.95 million, a price-to-earnings ratio of -0.67 and a beta of 1.55.

Nyxoah (NASDAQ:NYXH) last issued its earnings results on Tuesday, May 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.11. The firm had revenue of $7.38 million for the quarter, compared to analysts’ expectations of $7.05 million. Nyxoah had a negative net margin of 543.21% and a negative return on equity of 163.73%. Equities analysts forecast that Nyxoah will post -1.67 earnings per share for the current year.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.